Postoperative Nausea and Vomiting

5
Pipeline Programs
4
Companies
5
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
1
2
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

E
EisaiChina - Liaoning
2 programs
1
1
Palonosetron 0.075 mg IVPhase 41 trial
OndansetronPhase 21 trial
Active Trials
NCT00967499Completed239Est. Dec 2009
NCT02635828Completed40Est. Oct 2011
City Therapeutics
City TherapeuticsMA - Cambridge
1 program
1
GlycopyrroniumPhase 41 trial
Active Trials
NCT05265507UnknownEst. May 2023
Qilu Pharmaceutical
Qilu PharmaceuticalChina - Jinan
1 program
1
Aprepitant InjectionPhase 31 trial
Active Trials
NCT06932107CompletedEst. Jun 2024
Stuart Therapeutics
1 program
1
Aromatherapy inhalerPhase 21 trial
Active Trials
NCT02663154CompletedEst. Jul 2015

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
City TherapeuticsGlycopyrronium
EisaiPalonosetron 0.075 mg IV
Qilu PharmaceuticalAprepitant Injection
Stuart TherapeuticsAromatherapy inhaler
EisaiOndansetron

Clinical Trials (5)

Total enrollment: 279 patients across 5 trials

NCT05265507City TherapeuticsGlycopyrronium

Comparison of Postoperative Anti-nausea and Vomiting Effect Between Glycopyrronium and Ondansetron

Start: Mar 2022Est. completion: May 2023
Phase 4Unknown
NCT02635828EisaiPalonosetron 0.075 mg IV

Effectiveness of Triple Therapy With Palonosetron for PON Prophylaxis

Start: Oct 2009Est. completion: Oct 201140 patients
Phase 4Completed
NCT06932107Qilu PharmaceuticalAprepitant Injection

Efficacy and Safety Study of Aprepitant Injection for Prevention of Post-operative Nausea and Vomiting

Start: Feb 2024Est. completion: Jun 2024
Phase 3Completed
NCT02663154Stuart TherapeuticsAromatherapy inhaler

Aromatherapy for Postoperative Nausea and Vomiting in Children

Start: Jul 2014Est. completion: Jul 2015
Phase 2Completed
NCT00967499EisaiOndansetron

Pilot Study to Assess Palonosetron Versus Ondansetron as Rescue Medication in Subjects That Develop Postoperative Nausea and Vomiting (PONV) in the Postanesthesia Care Unit (PACU)

Start: Jul 2009Est. completion: Dec 2009239 patients
Phase 2Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
4 companies competing in this space